Mount Sinai Health System Hospital Campuses: Beth Israel Medical Center • Beth Israel Brooklyn • The Mount Sinai Hospital
|Home | Find A Doctor | Contact Us|
A Randomized Double-blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma
Bevacizumab has shown significant clinical activity in other cancer types.
It has been successfully combined with gemcitabine and cisplatin in other
diseases. Based on the evidence from other research studies that have
found TCC is a chemo-sensitive disease, and that bevacizumab improves
chemotherapy delivery, locally advanced or metastatic Transitional cell
carcinoma represents an opportunity to further explore this treatment
Please call for more information.
Copyright © Icahn School of Medicine at Mount Sinai |